Chondrosarcoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Chondrosarcoma – Drugs In Development, 2024 report and make more profitable business decisions.
Chondrosarcoma is a malignant cancer whose tumor cells produce a pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, and changes in urination. Treatment includes chemotherapy and radiation therapy.
The Chondrosarcoma drugs in development market research report provide comprehensive information on the therapeutics under development for Chondrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Chondrosarcoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 34 molecules, with 33 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Chondrosarcoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Chondrosarcoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Chondrosarcoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aadi Bioscience IncADC Therapeutics SA
Astex Pharmaceuticals Inc
Atlanthera
Bayer AG
BioAtla Inc
BioMed Valley Discoveries Inc
Bristol-Myers Squibb Co
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Clinigen Ltd
Coherus BioSciences Inc
EpicentRx Inc
Eucure (Beijing) Biopharma Co Ltd
Hutchison MediPharma Ltd
Incyte Corp
Inhibrx Inc
Iovance Biotherapeutics Inc
Ipsen SA
Jiangsu Hengrui Medicine Co Ltd
Les Laboratoires Servier SAS
Merck & Co Inc
Mural Oncology Inc
Nanode Therapeutics Inc
Nerviano Medical Sciences SRL
NKGen Biotech Inc
Pfizer Inc
Pharma Mar SA
Rigel Pharmaceuticals Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Junshi Biosciences Co Ltd
University of Miami
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Chondrosarcoma reports